Press Releases Keyword Search Year: 202120202019201820172016201520142013 Dec 10, 2017 Summary ToggleAgios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency Dec 5, 2017 Summary ToggleAgios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors Nov 17, 2017 Summary ToggleAgios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma Nov 1, 2017 Summary ToggleAgios to Present New Data from PKR and IDH Programs at the 2017 ASH Annual Meeting Nov 1, 2017 Summary ToggleAgios Reports Third Quarter 2017 Financial Results Oct 31, 2017 Summary ToggleAgios to Present at the 26th Annual Credit Suisse Healthcare Conference Tuesday, November 7, 2017 Oct 25, 2017 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2017 Financial Results on November 1, 2017 Sep 5, 2017 Summary ToggleAgios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017 Aug 8, 2017 Summary ToggleAgios Reports Second Quarter 2017 Financial Results Aug 3, 2017 Summary ToggleAgios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 Aug 1, 2017 Summary ToggleFDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation Jul 28, 2017 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 Jun 24, 2017 Summary ToggleNew Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML Jun 24, 2017 Summary ToggleAgios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency Jun 6, 2017 Summary ToggleUpdated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation Jun 3, 2017 Summary ToggleAgios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma May 31, 2017 Summary ToggleAgios Appoints David Scadden, M.D., to the Board of Directors May 18, 2017 Summary ToggleAgios to Present Updated Clinical Data from PKR Activator AG-348 at EHA May 17, 2017 Summary ToggleAgios to Present New Clinical Data from its IDH Programs at ASCO May 4, 2017 Summary ToggleAgios Reports First Quarter 2017 Financial Results Apr 28, 2017 Summary ToggleAgios Announces Closing of Over-Allotment Option in Public Offering Apr 27, 2017 Summary ToggleAgios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target Apr 27, 2017 Summary ToggleAgios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017 Apr 26, 2017 Summary ToggleAgios Announces Exercise of Over-Allotment Option in Public Offering Apr 24, 2017 Summary ToggleAgios Announces Closing of Public Offering Apr 18, 2017 Summary ToggleAgios Announces Pricing of $250 Million Public Offering of Common Stock Apr 17, 2017 Summary ToggleAgios Announces Proposed Offering of Common Stock Mar 30, 2017 Summary ToggleAgios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017 Mar 13, 2017 Summary ToggleAgios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene Mar 1, 2017 Summary ToggleFDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation Feb 28, 2017 Summary ToggleAgios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 Feb 16, 2017 Summary ToggleAgios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones Feb 9, 2017 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017 Jan 9, 2017 Summary ToggleAgios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017 Jan 3, 2017 Summary ToggleAgios Appoints Ian Clark to Board of Directors Jan 3, 2017 Summary ToggleAgios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 Dec 15, 2016 Summary ToggleAgios Provides Update on PKR Program Dec 5, 2016 Summary ToggleAgios Announces New Clinical Data from Dose-Escalation Portion of Phase 1 Trial of Single Agent AG-120 Showing Durable Molecular Responses in Patients with Advanced Hematologic Malignancies Dec 4, 2016 Summary ToggleAgios Announces New Data from AG-348 and AG-519 Demonstrating Potential for First Disease-modifying Treatment for Patients with PK Deficiency Nov 18, 2016 Summary ToggleAgios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma Nov 3, 2016 Summary ToggleAgios to Present New Data from PKR and IDH Programs at the 2016 ASH Annual Meeting Nov 3, 2016 Summary ToggleAgios Reports Third Quarter 2016 Financial Results and Reviews Recent Progress in IDH and PKR Development Programs Nov 1, 2016 Summary ToggleAgios to Present at the 25th Annual Credit Suisse Healthcare Conference Tuesday, November 8, 2016 Oct 27, 2016 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016 Oct 12, 2016 Summary ToggleCelgene and Agios Announce Collaborations with Abbott for Diagnostic Identification of IDH Mutations in AML Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last